[1] | Smith, M. R., Saad, F., Chowdhury, S., et al. (2021). Apalutamide and overall survival in prostate cancer. Eur. Urol. 79: 150−158. DOI: 10.1016/j.eururo.2020.08.011. |
[2] | Skoulidis, F., Li, B. T., Dy, G. K., et al. (2021). Sotorasib for lung cancers with KRAS p.G12C mutation. N. Engl. J. Med. 384: 2371–2381. DOI: 10.1056/NEJMoa2103695. |
[3] | Diaz, L. A. Jr, Shiu, K. K., Kim, T. W., et al. (2022). Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): Final analysis of a randomised, open-label, phase 3 study. Lancet Oncol. 23: 659−670. DOI: 10.1016/S1470-2045(22)00197-8. |
Du X., Lu X., and Cao X. (2023). Gantt chart for updated OS and PFS after cancer targeted therapy. The Innovation Medicine 1(1), 100008. https://doi.org/10.59717/j.xinn-med.2023.100008 |
To request copyright permission to republish or share portions of our works, please visit Copyright Clearance Center's (CCC) Marketplace website at marketplace.copyright.com.
The Gantt chart for mOS and mPFS of cancers.